Nayef Alzahrani1,2,3, Lawson Ung1,2, Sarah J Valle1,2, Winston Liauw1,2,4, David L Morris1,2. 1. Department of Surgery, University of New South Wales, Sydney, New South Wales, Australia. 2. Department of Surgical Oncology, St George Hospital, Sydney, New South Wales, Australia. 3. College of Medicine, Al-Iman Muhammad Ibn Saud Islamic University, Riyadh, Saudi Arabia. 4. Cancer Care Centre, St George Hospital, Sydney, New South Wales, Australia.
Abstract
BACKGROUND: Treatment of peritoneal metastases (PM) and liver metastases (LM) from colon cancer remains controversial. LM has been viewed as exclusion criterion for cytoreductive surgery (CRS) on the basis that such spread represents systemic disease. CRS and intraperitoneal chemotherapy (IPC) has gained increasing recognition as a treatment modality for selected patients with colon cancer and PM. This study analyses results of CRS and IPC for colon cancer and synchronous resection for treatment of LM and PM. METHODS: Seventy-eight patients with PM/LM colon cancer were analysed. Forty-two patients with PM were treated for disease limited to the peritoneum (A), and 36 patients received treatment for both PM and LM (B). Overall survival (OS), disease-free survival (DFS), morbidity, mortality and recurrence were compared. RESULTS: Median OS and DFS was 32.8 and 13.5 months. The median OS for A and B were 45.5 and 24.4 months respectively. Within B patients, 18 had a peritoneal carcinomatosis index (PCI) >7 and >3 LM and median survival of 21.8 months compared with 18 patients with PCI ≤7 and LM ≤3 with median survival of 38.4 months. Median DFS for A and B were 17.7 and 8.5 months respectively. Twenty-seven in total experienced major complications following surgery. Sixty-one patients recurred. Of A, 71.4% recurred compared with B at 86.1%. CONCLUSION: While our study is limited, it has demonstrated encouraging evidence that long-term survival outcomes can be achieved in this small but significant number of patients treated by CRS/IPC and additional synchronous liver resection with no significant increase in morbidity when compared with CRS/IPC alone.
BACKGROUND: Treatment of peritoneal metastases (PM) and liver metastases (LM) from colon cancer remains controversial. LM has been viewed as exclusion criterion for cytoreductive surgery (CRS) on the basis that such spread represents systemic disease. CRS and intraperitoneal chemotherapy (IPC) has gained increasing recognition as a treatment modality for selected patients with colon cancer and PM. This study analyses results of CRS and IPC for colon cancer and synchronous resection for treatment of LM and PM. METHODS: Seventy-eight patients with PM/LM colon cancer were analysed. Forty-two patients with PM were treated for disease limited to the peritoneum (A), and 36 patients received treatment for both PM and LM (B). Overall survival (OS), disease-free survival (DFS), morbidity, mortality and recurrence were compared. RESULTS: Median OS and DFS was 32.8 and 13.5 months. The median OS for A and B were 45.5 and 24.4 months respectively. Within B patients, 18 had a peritoneal carcinomatosis index (PCI) >7 and >3 LM and median survival of 21.8 months compared with 18 patients with PCI ≤7 and LM ≤3 with median survival of 38.4 months. Median DFS for A and B were 17.7 and 8.5 months respectively. Twenty-seven in total experienced major complications following surgery. Sixty-one patients recurred. Of A, 71.4% recurred compared with B at 86.1%. CONCLUSION: While our study is limited, it has demonstrated encouraging evidence that long-term survival outcomes can be achieved in this small but significant number of patients treated by CRS/IPC and additional synchronous liver resection with no significant increase in morbidity when compared with CRS/IPC alone.
Authors: M Tonello; G Ortega-Perez; O Alonso-Casado; P Torres-Mesa; G Guiñez; S Gonzalez-Moreno Journal: Clin Transl Oncol Date: 2018-04-17 Impact factor: 3.405
Authors: Jordan M Cloyd; Sherif Abdel-Misih; John Hays; Mary E Dillhoff; Timothy M Pawlik; Carl Schmidt Journal: J Gastrointest Surg Date: 2018-04-30 Impact factor: 3.452
Authors: Rachel M Lee; Adriana C Gamboa; Michael K Turgeon; Mohammad Y Zaidi; Charles Kimbrough; Jennifer Leiting; Travis Grotz; Andrew J Lee; Keith Fournier; Benjamin Powers; Sean Dineen; Joel M Baumgartner; Jula Veerapong; Harveshp Mogal; Callisia Clarke; Gregory Wilson; Sameer Patel; Ryan Hendrix; Laura Lambert; Courtney Pokrzywa; Daniel E Abbott; Christopher J LaRocca; Mustafa Raoof; Jonathan Greer; Fabian M Johnston; Charles A Staley; Jordan M Cloyd; Shishir K Maithel; Maria C Russell Journal: J Surg Oncol Date: 2020-10-01 Impact factor: 3.454
Authors: Peixian Zhang; Lan Shi; Linjing Song; Yi Long; Kehua Yuan; Wanbao Ding; Lei Deng Journal: Cancer Manag Res Date: 2020-03-09 Impact factor: 3.989